Related Experiment Videos
Prevention of perinatal group B streptococcal disease: updated CDC guideline
Colleen K Cagno1, Jessie M Pettit, Barry D Weiss
1University of Arizona College of Medicine, Tucson, 85750, USA. colleen.cagno@uahealth.com
Insights
The CDC updated guidelines for preventing early-onset neonatal Group B Streptococcus (GBS) sepsis. New recommendations include using nucleic acid amplification tests and revised antibiotic protocols for pregnant individuals with penicillin allergies.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Infectious Diseases
Background:
- Group B Streptococcus (GBS) is a primary cause of early-onset neonatal sepsis in the US.
- Universal GBS screening for pregnant individuals at 35-37 weeks' gestation is standard practice.
- The Centers for Disease Control and Prevention (CDC) has released updated guidelines to prevent neonatal GBS disease.
Purpose of the Study:
- To outline the key changes in the updated CDC guideline for preventing early-onset neonatal GBS disease.
- To highlight modifications in diagnostic methods, treatment algorithms, and antibiotic recommendations.
- To emphasize the expanded application of the secondary prevention algorithm for newborns.
Main Methods:
- Review and analysis of the updated CDC guideline for GBS disease prevention.
- Identification of six significant changes in the guideline compared to previous recommendations.
- Focus on diagnostic testing, urine culture interpretation, management algorithms, and antibiotic choices.
Main Results:
- Recommendation to consider sensitive nucleic acid amplification tests (NAATs) for GBS detection.
- Clarification of positive urine culture threshold at ≥10^4 colony-forming units/mL.
- Separate management algorithms for preterm labor and preterm premature rupture of membranes.
- Updated penicillin G dosing for intrapartum chemoprophylaxis.
- Revised antibiotic regimens for penicillin-allergic individuals, including cefazolin, clindamycin, and vancomycin.
- Expansion of the secondary prevention algorithm to all infants, detailing evaluation and observation.
Conclusions:
- The updated CDC guideline incorporates advanced diagnostic tools and refined treatment strategies.
- Specific recommendations address antibiotic use in penicillin-allergic pregnant individuals.
- The revised approach aims to enhance the prevention of early-onset neonatal GBS disease across all infant risk categories.
Abstract:
Group B streptococcus is the leading cause of early-onset neonatal sepsis in the United States. Universal screening is recommended for pregnant women at 35 to 37 weeks' gestation. The Centers for Disease Control and Prevention recently updated its guideline for the prevention of early-onset neonatal group B streptococcal disease. The new guideline contains six important changes. First, there is a recommendation to consider using sensitive nucleic acid amplification tests, rather than just routine cultures, for detection of group B streptococcus in rectal and vaginal specimens. Second, the colony count required to consider a urine specimen positive is at least 104 colony-forming units per mL. Third, the new guideline presents separate algorithms for management of preterm labor and preterm premature rupture of membranes, rather than a single algorithm for both conditions. Fourth, there are minor changes in the recommended dose of penicillin G for intrapartum chemoprophylaxis. Fifth, the guideline provides new recommendations about antibiotic regimens for women with penicillin allergy. Cefazolin is recommended for women with minor allergies. For those at serious risk of anaphylaxis, clindamycin is recommended if the organism is susceptible [corrected] and vancomycin is recommended if there is clindamycin resistance or if susceptibility is unknown. [corrected]. Finally, the new algorithm for secondary prevention of early-onset group B streptococcal disease in newborns should be applied to all infants, not only those at high risk of infection. The algorithm clarifies the extent of evaluation and duration of observation required for infants in different risk categories.